<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377243</url>
  </required_header>
  <id_info>
    <org_study_id>V8</org_study_id>
    <nct_id>NCT04377243</nct_id>
  </id_info>
  <brief_title>Immunotherapy of Chronic Kidney Failure</brief_title>
  <official_title>Phase II Trial of V8 in Treating Kidney Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunitor LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunitor LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kidney failure can result from inflammatory renal disease in the context of autoimmunity
      because the kidney is targeted by host's immune response against self. There are many causes
      to this, but abnormal kidney function tests, i.e., BUN and creatinine, can reveal the
      disease. Oral delivery of kidney cells is ought to produce the immune tolerance - phenomenon
      is known as oral tolerance. Preliminary studies produced convincing evidence that this
      hypothesis holds true and has not produced any adverse side effects. Intended open label
      Phase II aims to confirm these findings.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 16, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>neither patients nor attending physician are aware</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on creatinine</measure>
    <time_frame>1 month</time_frame>
    <description>Change in serum creatinine level from baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Renal Failure Chronic</condition>
  <arm_group>
    <arm_group_label>V8 850 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of V8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 850 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm: 2 Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V8</intervention_name>
    <description>one pill per day either V8 or placebo</description>
    <arm_group_label>Placebo 850 mg</arm_group_label>
    <arm_group_label>V8 850 mg</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Baseline level of creatinine twice above normal

        Exclusion Criteria:

          -  Baseline level of creatinine normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aldar Bourinbaiar, MD/PhD</last_name>
    <phone>13014760930</phone>
    <email>aldar@immunitor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marina Tarakanovskaya, MD</last_name>
    <phone>+97695130306</phone>
    <email>info@immunitor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Immunitor LLC</name>
      <address>
        <city>Ulaanbaatar</city>
        <country>Mongolia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mongolia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 2, 2020</study_first_submitted>
  <study_first_submitted_qc>May 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

